Cardio Diagnostics Holdings (NASDAQ: CDIO) announced it will exhibit at four national benefits conferences in June to engage employers, brokers, union trustees, and plan administrators on strategies to address cardiovascular disease, a leading driver of health plan costs and workforce productivity losses. The company will showcase its AI-powered cardiovascular risk assessment offerings, including Epi+Gen CHD(TM), PrecisionCHD(TM), and the HeartRisk(TM) population insights platform, designed to identify at-risk individuals earlier and help benefits decision-makers better manage healthcare costs and outcomes.
Cardiovascular disease remains a significant burden on the U.S. healthcare system, accounting for substantial health plan expenditures and lost productivity. By leveraging artificial intelligence and genetic-epigenetic technology, Cardio Diagnostics aims to provide more precise and accessible risk assessments. The company's solutions are intended to enable earlier intervention, potentially reducing the incidence of heart attacks, strokes, and other cardiovascular events.
The HeartRisk(TM) population insights platform offers benefits decision-makers a tool to analyze and manage cardiovascular risk across their covered populations. This can help employers and plan sponsors design targeted wellness programs and allocate resources more effectively. Epi+Gen CHD(TM) and PrecisionCHD(TM) are clinical tests that integrate genetic and epigenetic markers to assess an individual's risk for coronary heart disease.
The four conferences provide a platform for Cardio Diagnostics to demonstrate how its technology can be integrated into employee benefits strategies. The company's participation underscores a growing trend among benefits professionals to adopt data-driven, personalized approaches to health management. By identifying high-risk individuals before a cardiac event occurs, employers can potentially reduce medical claims and improve workforce health.
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease.
For more information, visit the company’s newsroom at https://ibn.fm/CDIO. The full press release is available at https://ibn.fm/qFRHu.
This article contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual results to differ materially. Factors that could cause such differences are discussed in the company's filings with the SEC, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.
